ABSTRACT
Background & objectives: The Covid-19 pandemic has revolutionised how we receive services, with a huge shift to online delivery. Online health promotion tools could be a cost-effective and safe way to improve population health. We used mixed methods to explore user responses to an online cognitive health tool.Methods1528 months after completing an online tool, comprising a cognitive test, lifestyle questionnaire; and dietary and lifestyle behaviour feedback, 4826 participants completed an online survey about their perceptions of it; and questions about their capability, opportunity and motivation for behavioural change developed using the COM-B behaviour change model. We reported how responses to the behaviour change questionnaire predicted decisions to make lifestyle and dietary changes. 24 participants attended focus groups to further explore their responses.ResultsMost users reported that the tool was useful (88%), with 37% reporting they made lifestyle or dietary changes after using it. More positive responses to questions regarding capability and motivation predicted making changes. Over a third (36%) felt more fearful after completing the tool. In qualitative findings, we identified barriers to engagement across the three COM-B domains: a sense that information was nothing new (so did not enhance capability); that experts dont agree and that the tool may not be credible (influencing motivation), and a lack of support from peers and lower availability of healthy food (reducing opportunities for change).ConclusionsFuture e-health tools will be most effective if they have high credibility, demonstrate advice is evidence-based and provide opportunities for support and follow up. (AU)
Subject(s)
Humans , Severe acute respiratory syndrome-related coronavirus , Coronavirus Infections/epidemiology , Health Promotion , Life StyleSubject(s)
Prostatic Neoplasms/drug therapy , Randomized Controlled Trials as Topic/methods , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Celecoxib , Diphosphonates/therapeutic use , Docetaxel , Humans , Imidazoles/therapeutic use , Male , Neoplasm Metastasis , Pilot Projects , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Taxoids/therapeutic use , Zoledronic AcidSubject(s)
Androgen Antagonists/therapeutic use , Anilides/therapeutic use , Gonadotropin-Releasing Hormone/analogs & derivatives , Nitriles/therapeutic use , Prostatic Neoplasms , Tosyl Compounds/therapeutic use , Combined Modality Therapy , Humans , Male , Prostate-Specific Antigen/blood , Prostatectomy , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/surgery , Radiotherapy, Adjuvant/methods , Salvage Therapy/methodsSubject(s)
Urinary Tract Infections/diagnosis , Bacteria/analysis , Child , Child, Preschool , Family Practice , Female , Humans , Infant , Male , Recurrence , Urinary Tract Infections/drug therapy , Urine/microbiologyABSTRACT
In a double-blind trial 45 children aged 6 months to 14 years with Escherichia coli infections of the urinary tract were given co-trimoxazole for two weeks and then allotted at random to one of two treatment groups for the remainder of six months; one continued with the active drug and the other with dummy tablets of identical appearance. Of the 24 children who took co-trimoxazole for two weeks and the 21 who took it for six months, 11 and 10, respectively, remained without further infections for at least a year. Over 90% of the reinfections occurred within five months of stopping the antibiotics, and the longer treatment did not cause any delay in their appearance. Thus probably a six-month course of treatment is no more likely to achieve a cure than a two-week course; nevertheless, no infection occurred during treatment, and there may be an advantage in continuing with antibiotics in small dosage.
